Storia in 11 fonti

Novartis stock in hot water after another key failure

The drugmaker saw its second late-stage trial miss in days, and Wall Street is now questioning its growth targets.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

thestreet.comStai leggendo1 g fa

Novartis stock in hot water after another key failure

Novartis dropped 14% after del-desiran failed Phase III; second major late-stage failure in days alongside CAR-T therapy pauses. Pipeline crisis amid patent expirations challenges 5-6% growth target; expensive acquisitions ahead risk shareholder dilution as stable-giant premium erodes.

originale

Timeline cronologica

martedì 8 settembre 2026·cnbc.com
Pharma major Novartis falls 10% after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
martedì 8 settembre 2026·endpoints.news
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
Novartis' del-desiran misses HARBOR trial's primary endpoint, adding to pelacarsen miss and CAR-T deaths; shares sink 10%.

Novartis stock in hot water after another key failure

Confronto fonti

Novartis stock in hot water after another key failure

Timeline cronologica

Pharma major Novartis falls 10% after three drug trial setbacks

Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug

Novartis shares plummet after another clinical trial setback

Pharma major Novartis falls 10% after three drug trial setbacks

Novartis del-desiran drug trial fails, stock drops 9%

Novartis secoué en bourse après une succession d’échecs cliniques - Le Temps

Novartis investors turn spotlight on M&A after trial setbacks

Novartis Sees Avidity Drug Fail in Third Setback in a Week

Tercer revés para Novartis en pocos días: la farmacéutica se derrumba en Bolsa tras los malos resultados de un medicamento muscular

Novartis del-desiran drug trial fails, stock drops 9%

Novartis shares plummet after another clinical trial setback

Novartis verliert 24 Milliarden Börsenwert nach Medikamenten-Rückschlägen

Nach Studienfehlschlägen: Aktien von Novartis stehen vor Bewährungsprobe

Novartis secoué en bourse après une succession d’échecs cliniques - Le Temps

Novartis stock in hot water after another key failure

Novartis investors turn spotlight on M&A after trial setbacks

Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks - Novartis (N

Drug Trial Setbacks Raise Questions Over Novartis (NVS)’s Growth Pipeline